Philippe Merle

Umr Inserm U1052 Cnrs5286, Crcl, 151
Lyon, 69008, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 138 publications

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: February 15, 2026

Second-line practices in the era of immunotherapy in HCC: The CHIEF cohort.

Second-line practices in the era of immunotherapy in HCC: The CHIEF cohort.

Journal: JHEP reports : innovation in hepatology

Published: October 20, 2025

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.

Journal: Journal of hepatology

Published: October 17, 2025

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative.

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative.

Journal: Journal of hepatology

Published: October 17, 2025

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).

Journal: Hepatology (Baltimore, Md.)

Published: October 16, 2025

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.

Journal: Annals of hepatology

Published: October 03, 2025

Multibipolar radiofrequency vs single needle microwave ablation for the treatment of newly diagnosed hepatocellular carcinoma.

Multibipolar radiofrequency vs single needle microwave ablation for the treatment of newly diagnosed hepatocellular carcinoma.

Journal: World journal of gastroenterology

Published: September 04, 2025

Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.

Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.

Journal: European journal of gastroenterology & hepatology

Published: August 13, 2025

A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data.

A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: July 08, 2025

Frizzled 7 drives amplification of cancer stem-cell subpopulations and the aggressiveness and poor differentiation of human hepatocellular carcinoma.

Frizzled 7 drives amplification of cancer stem-cell subpopulations and the aggressiveness and poor differentiation of human hepatocellular carcinoma.

Journal: PloS one

Published: May 30, 2025

Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study.

Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study.

Journal: Liver cancer

Published: April 14, 2025

Showing 1-12 of 138

Last Updated: 09/26/2026